Cyclacel Pharmaceuticals (NASDAQ:CYCC) Posts Earnings Results

Cyclacel Pharmaceuticals (NASDAQ:CYCC) announced its earnings results on Tuesday. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.36, Zacks reports. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%.

Cyclacel Pharmaceuticals Price Performance

Shares of CYCC opened at $0.40 on Thursday. The firm has a 50 day simple moving average of $0.88 and a two-hundred day simple moving average of $1.44. Cyclacel Pharmaceuticals has a one year low of $0.37 and a one year high of $6.00. The company has a market cap of $854,625.00, a P/E ratio of -0.05 and a beta of 0.56.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CYCC. StockNews.com assumed coverage on Cyclacel Pharmaceuticals in a research report on Thursday, November 7th. They set a “sell” rating on the stock. Roth Capital cut Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.